# OLUMIANT® (baricitinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/baricitinib

> The FDA approved OLUMIANT® (baricitinib), sponsored by ELI LILLY & Co (LLY), on May 31, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | OLUMIANT® (baricitinib) |
| Codes | LY3009104 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Systemic Juvenile Idiopathic Arthritis](https://sec-api.dev/indications/systemic-juvenile-idiopathic-arthritis), Areata Alopecia, [Diabetes Mellitus, Type 1](https://sec-api.dev/indications/diabetes-mellitus-type-1) |
| Modality | small_molecule |
| FDA designations | breakthrough, priority review |

## Timeline

### May 31, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207924 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180531, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22

### May 10, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207924 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20220510, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22

### June 13, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-10, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207924 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220613, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22
- SEC Form 10-Q (accession 0000879169-25-000103): "In June 2022, we and Lilly announced the FDA approved baricitinib as OLUMIANT for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or ECMO." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In June 2022, we and Lilly announced the FDA approved baricitinib as OLUMIANT for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or ECMO." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In June 2022, we and Lilly announced the FDA approved baricitinib as OLUMIANT for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation or ECMO." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### September 25, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207924 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260925, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Systemic Juvenile Idiopathic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04088396 (A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT04088396

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Systemic Juvenile Idiopathic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04088396 (A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT04088396

### October 9, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207924 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20261009, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Areata Alopecia; Alopecia; Hypotrichosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05723198 (A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05723198

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Areata Alopecia; Alopecia; Hypotrichosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05723198 (A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05723198

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diabetes Mellitus, Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07222332 (A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07222332

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diabetes Mellitus, Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07222332 (A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07222332

## Same indication

- [Cadisegliatin](https://sec-api.dev/pdufa/cadisegliatin) (VTVT)
- [Dasiglucagon](https://sec-api.dev/pdufa/dasiglucagon) (NVO)
- [Awiqli Flextouch (insulin icodec)](https://sec-api.dev/pdufa/insulin-icodec) (NVO)
- [Zimislecel](https://sec-api.dev/pdufa/zimislecel) (VRTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/baricitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OLUMIANT® (baricitinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/baricitinib

```bibtex
@misc{secapidev_pdufa_baricitinib_20261116,
  title        = {OLUMIANT® (baricitinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/baricitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_baricitinib_20261116","title":"OLUMIANT® (baricitinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/baricitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
